Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06244901
Other study ID # 2137424
Secondary ID
Status Recruiting
Phase Early Phase 1
First received
Last updated
Start date October 25, 2023
Est. completion date September 1, 2025

Study information

Verified date January 2024
Source Northern Arizona University
Contact Zach Lerner, PhD
Phone 928-523-1787
Email Zachary.Lerner@nau.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This feasibility study looks to evaluate ankle exoskeleton assistance in community settings for individuals with cerebral palsy.


Description:

Participants will undergo consent (if not done over the phone), history/physical/activity questionnaire, and orthotic device fitting. Following device fitting, the participants will practice walking with powered assistance. Next, participants will complete "pre" walking tests with and without the device (order randomized) on a 15-minute pre planned community walk in close proximity with their own home. Distance, time, heart-rate, and perceived exertion will be recorded. The expected duration is 1-2 hours. Next, participants will be asked to complete (under parental supervision for minors) the pre-determined walking route every day for 1 week with or without ankle exoskeleton assistance (block randomized). Following the first week of independent walking practice, participants will complete "post" walking tests with and without the device on the same walking route. Distance, time, heart-rate, and perceived exertion will be recorded. The expected duration is 1-2 hours. Participants will then have a 2-6 week washout period. Following this washout, the pre- and post-assessments will be completed before and after, respectively, another week of identical community walking practice completed under the remaining condition (either exoskeleton or no exoskeleton).


Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date September 1, 2025
Est. primary completion date May 1, 2025
Accepts healthy volunteers No
Gender All
Age group 12 Years to 45 Years
Eligibility Inclusion Criteria: - Diagnosis of cerebral palsy - Gross Motor Function Classification Level I, II, or III - Able to walk for at least 20 minutes with or without a walking aid - Able to safely fit into a device configuration and tolerate assistance without knee hyperextension while walking - Able to provide verbal assent, if appropriate. If the participant is non-verbal, parental interpretation of gesticulation for assent will be used. Exclusion Criteria: - Any neurological, musculoskeletal or cardiorespiratory injury, health condition ( including pregnancy), or diagnosis other than cerebral palsy that would affect the ability to walk as directed for short periods of time. - Participant or parent report that the perspective participant's physician has recommended that they not engage in moderate intensity walking exercise.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Ankle Exoskeleton
Walking for twenty minutes with a wearable powered robotic ankle exoskeleton on real-world terrain every day for a week.
Other:
Normal walking
Normal walking for twenty minutes on real-world terrain every day for a week.

Locations

Country Name City State
United States Northern Arizona University Flagstaff Arizona

Sponsors (1)

Lead Sponsor Collaborator
Northern Arizona University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Walking speed Change in walking speed (measured in meters per second) through study completion, an average of one week
Secondary Step length Change in step length (measured in meters) Through study completion, an average of one week
Secondary Heart-rate Change in heart rate (measured in beats per minute) Through study completion, an average of one week
Secondary Perceived exertion Change in perceived exertion (measured on a 1-10 scale) Through study completion, an average of one week
See also
  Status Clinical Trial Phase
Recruiting NCT05317234 - Genetic Predisposition in Cerebral Palsy N/A
Recruiting NCT05576948 - Natural History of Cerebral Palsy Prospective Study
Completed NCT04119063 - Evaluating Wearable Robotic Assistance on Gait Early Phase 1
Completed NCT03264339 - The Small Step Program - Early Intervention for Children With High Risk of Developing Cerebral Palsy N/A
Completed NCT05551364 - Usability and Effectiveness of the ATLAS2030 Exoskeleton in Children With Cerebral Palsy N/A
Completed NCT03902886 - Independent Walking Onset of Children With Cerebral Palsy
Recruiting NCT05571033 - Operant Conditioning of the Soleus Stretch Reflex in Adults With Cerebral Palsy N/A
Not yet recruiting NCT04081675 - Compliance in Children With Cerebral Palsy Supplied With AFOs
Completed NCT02167022 - Intense Physiotherapies to Improve Function in Young Children With Cerebral Palsy N/A
Completed NCT04012125 - The Effect of Flexible Thoracolumbar Brace on Scoliosis in Cerebral Palsy N/A
Enrolling by invitation NCT05619211 - Piloting Movement-to-Music With Arm-based Sprint-Intensity Interval Training Among Children With Physical Disabilities Phase 1
Completed NCT04489498 - Comparison of Somatometric Characteristics Between Cerebral Palsy and Normal Children, Cross-sectional, Multi Center Study
Completed NCT03677193 - Biofeedback-enhanced Interactive Computer-play for Youth With Cerebral Palsy N/A
Recruiting NCT06450158 - Robot-assisted Training in Children With CP N/A
Completed NCT04093180 - Intensive Neurorehabilitation for Cerebral Palsy N/A
Completed NCT02909127 - The Pediatric Eating Assessment Tool
Not yet recruiting NCT06377982 - Human Umbilical Cord Blood Infusion in Patients With Cerebral Palsy Phase 1
Not yet recruiting NCT06007885 - Examining Capacity Building of Youth With Physical Disabilities to Pursue Participation Following the PREP Intervention. N/A
Not yet recruiting NCT03183427 - Corpus Callosum Size in Patients With Pineal Cyst N/A
Active, not recruiting NCT03078621 - Bone Marrow-Derived Stem Cell Transplantation for the Treatment of Cerebral Palsy Phase 1/Phase 2